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Use of the biguanide metformin, an AMPK activator, is associated with a reduced incidence of cancer in
diabetics, but it has been unclear whether this requires AMPK. In this issue of Cancer Cell, Shackelford
and colleagues show, paradoxically, that biguanides are more effective in the treatment of mouse tumors
that lack a functional LKB1-AMPK pathway.Ten years ago, LKB1 was found to be the
crucial upstream kinase required for acti-
vation of AMP-activated protein kinase
(AMPK) (reviewed in Hardie, 2004). This
finding placed a protein kinase known to
be a tumor suppressor (LKB1) upstream
of a kinase involved in regulation of
metabolism in response to energy stress
(AMPK). AMPK was already known to be
activated by the anti-diabetic drug met-
formin. Putting these findings together,
Morris and Alessi analyzed retrospective
data from a cohort of patients with type
2 diabetes (T2D) and found that use of
metformin rather than other medications
was associated with a 30% lower cancer
incidence (Evans et al., 2005). This
association has since been observed in
other diabetic cohorts, but the mecha-
nism by which metformin might protect
against cancer has been the subject of
much debate. In a study reported in this
issue of Cancer Cell, Shackelford et al.
(2013) use a mouse model to show that
the related drug phenformin appears,
paradoxically, to be more effective in the
treatment of non-small cell lung cancer
(NSCLC) if the tumors lack a functional
LKB1-AMPK pathway, suggesting that
the latter can sometimes be a ‘‘foe’’ rather
than a ‘‘friend’’ in cancer.
Metformin and phenformin, first used
over 50 years ago for the treatment of
T2D, are related biguanide drugs. Phen-
formin was withdrawn in most countries
because of the serious but rare side effect
of lactic acidosis, whereas metformin has
become the drug of first choice in T2D.
Both are cations that accumulate in mito-
chondria due to the charge gradient
across the inner membrane, where they
inhibit complex I of the respiratory chain
(Owen et al., 2000). This causes depletion
of cellular ATP and increases ADP and
AMP, which is why they activate AMPK(Hawley et al., 2010). However, given the
ubiquitous role of these nucleotides in
cell function, it is not surprising that
many AMPK-independent effects are
now being documented.
At least three mechanisms can be
proposed to explain the effects of metfor-
min on cancer (Figure 1). Mechanism 1 is
based on its known insulin-sensitizing
and anti-hyperglycemic effects. Humans
with T2D have an increased cancer inci-
dence, and their high plasma insulin
and/or glucose levels, which provide a
cellular environment conducive to tumor
growth, might be the culprits. By revers-
ing hyperglycemia, and hence hyperse-
cretion of insulin, metformin lowers
plasma insulin as well as glucose. This
could account in part for the protective
effects of metformin in diabetics, but it
cannot explain the effects in rodent
models where the animals were not
insulin-resistant. Two alternative hypoth-
eses, both involving direct effects of met-
formin on tumor cells themselves, can be
proposed in such cases. In mechanism 2,
metformin activates AMPK in the tumor or
pre-tumor cells, restraining their growth
and proliferation. In addition, AMPK has
been shown to oppose the Warburg
effect, the switch from oxidative metabo-
lism to glycolysis commonly observed
in tumor cells (Faubert et al., 2013).
Mechanism 3 is based on findings that
LKB1-deficient cells are more prone to
apoptosis in response to metabolic stress
(Shaw et al., 2004) and that metformin
causes a greater depletion of ATP in
cells that are AMPK-deficient and there-
fore have defective energy homeostasis
(Foretz et al., 2010). Up to 30% of
NSCLCs (Ji et al., 2007) and smaller
proportions of other cancers display
loss-of-function mutations in LKB1. In
such tumors, the ATP-depleting proper-Cancer Cell 23,ties of metformin might promote cell
death.
Although it focues on phenformin rather
than metformin, the new study by Shack-
elford et al. (2013) helps to distinguish
between mechanisms 2 and 3. Starting
with a K-Ras mutant and LKB1 null
NSCLC cell line, they found that phenfor-
min had a larger effect than metformin
on ATP levels, while only phenformin
triggered apoptosis. Similar results were
obtained in other NSCLC lines, where
apoptosis triggered by phenformin corre-
lated strictly with LKB1 loss but not with
other mutations. They went on to use a
mouse model of NSCLC in which expres-
sion of mutant K-Ras, either alone or
combined with loss of either LKB1 or
p53, was selectively triggered in lung
epithelial cells by intratracheal adminis-
tration of viral vectors encoding Cre re-
combinase (Ji et al., 2007). As observed
previously, the tumor burden was greatly
increased when mutant K-Ras was
combined with the loss of LKB1 or p53.
In the tumors that still expressed LKB1,
phenformin caused more AMPK phos-
phorylation than metformin, so further
experiments focused on phenformin
(although these results did confirm that
both drugs were reaching the tumor cells
and causing energy stress). They next
tested two protocols, one giving phenfor-
min in drinking water 6 weeks after tumor
initiation and the other by daily oral
gavage after 3weeks. In the former, phen-
formin seemed to cause modest reduc-
tions in tumor burden and increased
markers of tumor apoptosis in all three
genotypes, although these effects were
only statistically significant in the LKB1
null tumors. In the latter, phenformin
enhanced overall survival of the mice by
several weeks, while tumor volume and
fluorodeoxyglucose uptake (a marker ofFebruary 11, 2013 ª2013 Elsevier Inc. 131
Figure 1. Three Alternate Mechanisms to Explain Protective Effects of Biguanides in Cancer
In mechanism 1, whichwould only operate in insulin-resistant individuals, the drugs lower plasma glucose,
and thus increase the secretion of insulin from the pancreas. The consequent drop in plasma insulin and
glucose reverses the favorable environment for tumor cell growth. In mechanism 2, they activate AMPK in
the pretumor cell, exerting a cytostatic effect and preventing themetabolic switch to theWarburg effect. In
mechanism 3, they selectively reduce ATP levels in tumor cells with a nonfunctional LKB1-AMPK pathway
due to their inability to respond to energy stress, thus triggering cell death. All three mechanisms might
operate in different cases of cancer, while mechanisms 1 and 2 or 1 and 3, could conceivably coexist
in a single case.
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Previewsthe Warburg effect) were lower after
4 weeks of treatment, but, crucially, all
of these effects were only seen in the
tumors that had lost LKB1.
Because the mice used in these studies
were not diabetic or insulin-resistant,
phenformin did not reduce plasma
glucose or insulin, ruling out mechanism
1. In addition, because the beneficial
effects were only observed in the LKB1
null cancers, they had to be direct, cell-
autonomous effects on the tumor cells
themselves. Overall, the results clearly
support mechanism 3 (i.e., that cells that
have lost a functional LKB1-AMPK path-
way are more sensitive to cell death
induced by phenformin) and not mecha-
nism 2 (i.e., that it works by activating
AMPK in the tumors). In this mechanism,
phenformin is effectively acting as a cyto-
toxic agent, but an attractive feature is
that normal cells would be resistant
because they have a functioning LKB1-
AMPK pathway. This raises the exciting
prospect that biguanides might be partic-
ularly useful for the treatment of those132 Cancer Cell 23, February 11, 2013 ª2013tumors where the LKB1-AMPK pathway
is downregulated. There are mechanisms
by which this happens, other than by
simple genetic loss of LKB1; for example,
although mutations in the LKB1 gene
appear to be rare in breast cancer, immu-
nohistochemical analyses suggest that
AMPK activation is frequently downregu-
lated (Hadad et al., 2009).
These results do not rule out the occur-
rence ofmechanisms 1 and 2 in other situ-
ations, particularly where biguanides may
be used to prevent rather than treat
cancer. Another caveat is that the benefi-
cial effects on tumor burden and fluoro-
deoxyglucose uptake observed after
4 weeks of phenformin treatment were
no longer significant after 6 weeks, sug-
gesting that phenformin resistance devel-
oped. This might arise as the cells start to
make more of their ATP by glycolysis and
become less dependent on mitochondrial
function. All of the mice did also eventu-
ally succumb to cancer despite treatment,
so phenformin is unlikely to be effective as
a single therapy.Elsevier Inc.One of the most interesting features of
this study was the focus on the use of
phenformin rather than metformin. The
effects of metformin on tumor burden or
survival were not tested, although its
smaller effects on AMPK in the tumors ex-
pressing LKB1, and its lack of effect on
apoptosis in the cell culture models
suggest that it would have been less
effective than phenformin. A possible
explanation of the greater effectiveness
of phenformin is that it is more cell-perme-
able than metformin, and its uptake into
cells is less dependent on expression of
organic cation transporters (Hawley
et al., 2010). Although phenformin was
withdrawn for use in T2D because of
cases of lactic acidosis, these were rare
(<1 case per 1,000 patient years), and
this frequency of side effect may be
more acceptable for the treatment of
cancer rather than diabetes.
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